Easterly Government Properties (DEA) Investor presentation summary

Targeted therapy and pipeline overview

• Focus on antibody-drug conjugates (ADCs) targeting CDH6 (SIM0505) and B7-H4 (LNCB74) for gynecologic and other cancers.

• SIM0505 and LNCB74 are in clinical development, with SIM0505 showing promising efficacy in ovarian and uterine serous carcinoma.

• SIM0505 has a global exclusive license (ex-China) and is being developed with data integration from US and China.

• LNCB74 is in dose escalation for breast, ovarian, endometrial, and ACC-1 cancers, with a focus on patient selection and safety.

SIM0505 clinical results and safety

• Achieved 55% overall response rate (ORR) in gynecologic cancers at therapeutic doses (4.8–8.0 mg/kg).

• Ovarian cancer ORR was 52.9%, and uterine serous carcinoma ORR was 66.7%.

• Most patients experienced tumor shrinkage, with greatest effects at 6.4 and 8.0 mg/kg.

• Safety profile is manageable; most adverse events were hematological and reversible, with no primary prophylaxis required.

• Fast track status granted for platinum-resistant ovarian cancer (PROC); pivotal trial planning underway.

SIM0505 development and next steps

• Dose optimization ongoing in US and China, with pivotal trial dose selection in progress.

• Expansion to additional sites in US, China, Canada, and Europe; supply chain and CDMO tech transfer initiated.

• Near-term development expansions considered for RCC and NSCLC indications.

• Next milestone: dose optimization update in 1Q 2027.